Repository logo
  • English
  • 中文
Log In
Have you forgotten your password?
  1. Home
  2. College of Medicine / 醫學院
  3. School of Medicine / 醫學系
  4. Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)-a trial by the Asian Myeloma Network
 
  • Details

Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)-a trial by the Asian Myeloma Network

Journal
Blood Cancer Journal
Journal Volume
9
Journal Issue
10
Date Issued
2019
Author(s)
Soekojo C.Y.
Kim K.
SHANG-YI HUANG  
Chim C.-S.
Takezako N.
Asaoku H.
Kimura H.
Kosugi H.
Sakamoto J.
Gopalakrishnan S.K.
Nagarajan C.
Wei Y.
Moorakonda R.
Lee S.L.
Lee J.J.
Yoon S.-S.
Kim J.S.
Min C.K.
Lee J.-H.
Durie B.
Chng W.J.
DOI
10.1038/s41408-019-0245-1
URI
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85073056680&doi=10.1038%2fs41408-019-0245-1&partnerID=40&md5=9e23e7c755b1c2ccf33570e224017a95
https://scholars.lib.ntu.edu.tw/handle/123456789/540524
Abstract
Pomalidomide is a third generation immunomodulatory drug which in combination with dexamethasone, has been shown to be active in relapsed/refractory multiple myeloma. However, the data in Asian patients remain limited. We conducted a prospective phase two clinical trial in major cancer centers in Singapore, South Korea, Taiwan, Japan and Hong Kong to assess the efficacy and safety of pomalidomide and dexamethasone combination (PomDex) +/? cyclophosphamide in Asian patients with relapsed/refractory multiple myeloma who failed lenalidomide and bortezomib. Patients were treated with pomalidomide (4 mg daily for 21 days every 4 weeks) and dexamethasone (40 mg weekly). If there is less than a minimal response after three cycles of PomDex, cyclophosphamide 300 mg/m2 can be added (PomCyDex). A total of 136 patients were enrolled. The median PFS was 9 and 10.8 months for the PomDex and PomCyDex group, respectively. The median OS was 16.3 months. This regimen appears to be active across age groups and prior lines of treatment. This combination was overall well tolerated with grade 3 and 4 adverse events of mainly cytopenias. PomDex is highly active and well-tolerated in Asian patients. The addition of cyclophosphamide can improve the response and outcomes further in patients with suboptimal response to PomDex. ? 2019, The Author(s).
SDGs

[SDGs]SDG3

Other Subjects
bortezomib; cyclophosphamide; dexamethasone; lenalidomide; pomalidomide; antineoplastic agent; cyclophosphamide; dexamethasone; pomalidomide; thalidomide; aged; anemia; anorexia; anxiety; Article; blurred vision; cancer center; cancer combination chemotherapy; cancer patient; cancer survival; clinical outcome; constipation; controlled study; coughing; diarrhea; dizziness; drug dose reduction; drug efficacy; drug safety; drug tolerability; dyspnea; edema; emotional disorder; fatigue; febrile neutropenia; female; fever; headache; heart failure; Hong Kong; human; hypercalcemia; hypernatremia; hypertension; hypocalcemia; hypokalemia; hypotension; insomnia; Japan; kidney dysfunction; liver function test; major clinical study; male; multicenter study; multiple cycle treatment; multiple myeloma; muscle spasm; muscle weakness; nausea; neuralgia; neutropenia; overall survival; pain; peripheral neuropathy; phase 2 clinical trial; pleura effusion; pneumonia; progression free survival; randomized controlled trial; rash; sepsis; side effect; Singapore; South Korea; survival rate; survival time; Taiwan; thrombocytopenia; treatment response; upper respiratory tract infection; urinary tract infection; vein thrombosis; vomiting; Asian continental ancestry group; clinical trial; disease free survival; drug effect; drug resistance; multiple myeloma; pathology; prospective study; tumor recurrence; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian Continental Ancestry Group; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Prospective Studies; Thalidomide
Publisher
Nature Publishing Group
Type
journal article

臺大位居世界頂尖大學之列,為永久珍藏及向國際展現本校豐碩的研究成果及學術能量,圖書館整合機構典藏(NTUR)與學術庫(AH)不同功能平台,成為臺大學術典藏NTU scholars。期能整合研究能量、促進交流合作、保存學術產出、推廣研究成果。

To permanently archive and promote researcher profiles and scholarly works, Library integrates the services of “NTU Repository” with “Academic Hub” to form NTU Scholars.

總館學科館員 (Main Library)
醫學圖書館學科館員 (Medical Library)
社會科學院辜振甫紀念圖書館學科館員 (Social Sciences Library)

開放取用是從使用者角度提升資訊取用性的社會運動,應用在學術研究上是透過將研究著作公開供使用者自由取閱,以促進學術傳播及因應期刊訂購費用逐年攀升。同時可加速研究發展、提升研究影響力,NTU Scholars即為本校的開放取用典藏(OA Archive)平台。(點選深入了解OA)

  • 請確認所上傳的全文是原創的內容,若該文件包含部分內容的版權非匯入者所有,或由第三方贊助與合作完成,請確認該版權所有者及第三方同意提供此授權。
    Please represent that the submission is your original work, and that you have the right to grant the rights to upload.
  • 若欲上傳已出版的全文電子檔,可使用Open policy finder網站查詢,以確認出版單位之版權政策。
    Please use Open policy finder to find a summary of permissions that are normally given as part of each publisher's copyright transfer agreement.
  • 網站簡介 (Quickstart Guide)
  • 使用手冊 (Instruction Manual)
  • 線上預約服務 (Booking Service)
  • 方案一:臺灣大學計算機中心帳號登入
    (With C&INC Email Account)
  • 方案二:ORCID帳號登入 (With ORCID)
  • 方案一:定期更新ORCID者,以ID匯入 (Search for identifier (ORCID))
  • 方案二:自行建檔 (Default mode Submission)
  • 方案三:學科館員協助匯入 (Email worklist to subject librarians)

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science